DK2425017T3 - Fremgangsmåde til typebestemmelse af humant papillomvirus HPV - Google Patents
Fremgangsmåde til typebestemmelse af humant papillomvirus HPV Download PDFInfo
- Publication number
- DK2425017T3 DK2425017T3 DK10769997T DK10769997T DK2425017T3 DK 2425017 T3 DK2425017 T3 DK 2425017T3 DK 10769997 T DK10769997 T DK 10769997T DK 10769997 T DK10769997 T DK 10769997T DK 2425017 T3 DK2425017 T3 DK 2425017T3
- Authority
- DK
- Denmark
- Prior art keywords
- hpv
- pcr
- oligonucleotide sequence
- group
- sequence seq
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 41
- 241000701806 Human papillomavirus Species 0.000 title description 82
- 239000000523 sample Substances 0.000 claims description 116
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 230000002441 reversible effect Effects 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims 4
- 230000000171 quenching effect Effects 0.000 claims 4
- 238000012360 testing method Methods 0.000 description 55
- 230000003321 amplification Effects 0.000 description 51
- 238000003199 nucleic acid amplification method Methods 0.000 description 51
- 230000035945 sensitivity Effects 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 23
- 239000013641 positive control Substances 0.000 description 21
- 241000341655 Human papillomavirus type 16 Species 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000007403 mPCR Methods 0.000 description 7
- 231100000590 oncogenic Toxicity 0.000 description 7
- 230000002246 oncogenic effect Effects 0.000 description 7
- 101100445488 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-2 gene Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000037029 cross reaction Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 101150075239 L1 gene Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011895 specific detection Methods 0.000 description 4
- 238000007400 DNA extraction Methods 0.000 description 3
- 208000009608 Papillomavirus Infections Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001648 catalysed chemiluminescence detection Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000001921 locked nucleotide group Chemical group 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (5)
1. Fremgangsmåde til samtidig påvisning og/eller typebestemmelse og/eller mængdebestemmelse af tilstedeværelsen af HPV 18, 52, 59, 39, 51, 56, 66, 16, 45, 58, 31, 33 og 35 i en biologisk prøve, idet fremgangsmåden omfatter følgende fire parallelle reaktioner: Reaktion 1-a) mangfoldiggørelse af nukleinsyrefragmenterne fra HPV 18, 52 og 59 i nærvær af (i) en nukleinsyrepolymerase, (ii) en fremadrettet PCR-primer med en oligonukleotidsekvens SEQ ID NO: 1, (iii) en revers PCR-primer med en oligonukleotidsekvens SEQ ID NO: 2, (iv) en sonde med en oligonukleotidsekvens SEQ ID NO: 7, 8 og 9, mærket med en fluorophor og et slukningsmolekyle og b) påvisning af en fluorescensændring, hvis bølgelængde bestemmer HPV-type 18, 52 og 59; reaktion 2-a) mangfoldiggørelse af nukleinsyrefragmenterne fra HPV 39, 51, 56 og 66 i nærvær af (i) en nukleinsyrepolymerase, (ii) en fremadrettet PCR-primer med en oligonukleotidsekvens SEQ ID NO: 1, (iii) en revers PCR-primer med en oligonukleotidsekvens SEQ ID NO: 3, (iv) en sonde med en oligonukleotidsekvens SEQ ID NO: 10, 11, 12 og 13, mærket med en fluorophor og et slukningsmolekyle og b) påvisning af en fluorescensændring, hvis bølgelængde bestemmer HPV-type 39, 51,56 og 66; reaktion 3-a) mangfoldiggørelse af nukleinsyrefragmenterne fra HPV 16, 45 og 58 i nærvær af (i) en nukleinsyrepolymerase, (ii) en fremadrettet PCR-primer med en oligonukleotidsekvens SEQ ID NO: 1, (iii) en revers PCR-primer med en oligonukleotidsekvens SEQ ID NO: 4, (iv) en sonde med en oligonukleotidsekvens SEQ ID NO: 14, 15 og 16, mærket med en fluorophor og et slukningsmolekyle og b) påvisning af en fluorescensændring, hvis bølgelængde bestemmer HPV-type 16, 45 og 58; Reaktion 4-a) mangfoldiggørelse af nukleinsyrefragmenterne fra HPV 31, 33 og 35 og en intern kontrol i nærvær af (i) en nukleinsyrepolymerase, (ii) en fremadrettet PCR-primer med en oligonukleotidsekvens SEQ ID NO: 1, (iii) en revers PCR-primer med en oligonukleotidsekvens SEQ ID NO: 5, (iv) en sonde med en oligonukleotidsekvens SEQ ID NO: 17, 18, 19 og 20, mærket med en fluorophor og et slukningsmolekyle og (v) en intern kontrol og b) påvisning af en fluorescensændring, hvis bølgelængde bestemmer HPV-type 31,33, 35 og den interne kontrol.
2. Fremgangsmåde ifølge krav 1, ved hvilken reaktionerne udføres parallelt og i særskilte hætteglas.
3. Fremgangsmåde ifølge krav 1 til 2, ved hvilken de fire fluorephorer er FAM, VIC, NED og ROX.
4. Fremgangsmåde ifølge krav 1 til 2, ved hvilken den interne kontrol er HPV6.
5. Sæt til samtidig påvisning og/eller typebestemmelse og/eller mængdebestemmelse af HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 og 66 i en biologisk prøve omfattende de fire primer-sonde-kombinationer som anvendt i krav 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20091733A NO330943B1 (no) | 2009-04-30 | 2009-04-30 | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. |
| PCT/NO2010/000147 WO2010126375A1 (en) | 2009-04-30 | 2010-04-22 | A method for detection of human papillomavirus (hpv) type |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2425017T3 true DK2425017T3 (da) | 2015-03-02 |
Family
ID=43032356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10769997T DK2425017T3 (da) | 2009-04-30 | 2010-04-22 | Fremgangsmåde til typebestemmelse af humant papillomvirus HPV |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8895247B2 (da) |
| EP (1) | EP2425017B1 (da) |
| CN (1) | CN102459631B (da) |
| AU (1) | AU2010242168B2 (da) |
| BR (1) | BRPI1007637A2 (da) |
| CA (1) | CA2760274A1 (da) |
| CY (1) | CY1116083T1 (da) |
| DK (1) | DK2425017T3 (da) |
| EA (1) | EA201171239A1 (da) |
| ES (1) | ES2534644T3 (da) |
| HR (1) | HRP20150190T1 (da) |
| IL (1) | IL216035A0 (da) |
| MX (1) | MX2011011521A (da) |
| MY (1) | MY160754A (da) |
| NO (1) | NO330943B1 (da) |
| NZ (1) | NZ596252A (da) |
| PL (1) | PL2425017T3 (da) |
| PT (1) | PT2425017E (da) |
| SA (1) | SA110310331B1 (da) |
| SG (1) | SG175825A1 (da) |
| SI (1) | SI2425017T1 (da) |
| WO (1) | WO2010126375A1 (da) |
| ZA (1) | ZA201108225B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO330943B1 (no) | 2009-04-30 | 2011-08-22 | Unilabs Telelabs As | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. |
| CN102994647B (zh) * | 2012-06-21 | 2014-11-19 | 宁波海尔施基因科技有限公司 | 一种人乳头瘤病毒(hpv)的分型定量检测试剂盒 |
| RU2520710C1 (ru) * | 2012-12-10 | 2014-06-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) | Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии |
| CN104818342B (zh) * | 2015-03-23 | 2017-09-22 | 厦门艾德生物医药科技有限公司 | 用于19种高危型人乳头瘤病毒(hpv)的检测试剂盒、检测体系及方法 |
| CN107849599A (zh) * | 2015-06-30 | 2018-03-27 | 优比欧迈公司 | 用于诊断测试的方法和系统 |
| CN109554506A (zh) * | 2016-01-15 | 2019-04-02 | 艾康生物技术(杭州)有限公司 | 一种用于检测病原体的引物和探针的设计方法 |
| US11441167B2 (en) * | 2019-11-20 | 2022-09-13 | Roche Molecular Systems, Inc. | Compositions and methods for rapid identification and phenotypic antimicrobial susceptibility testing of bacteria and fungi |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0357611B1 (en) * | 1987-02-26 | 1995-04-26 | The University Of Sydney | A method of detection of carcinogenic human papillomavirus |
| US5484699A (en) | 1990-09-28 | 1996-01-16 | Abbott Laboratories | Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| DK1012348T3 (da) * | 1997-09-16 | 2002-10-14 | Innogenetics Nv | Detektion og identifikation af humant papillomavirus ved PCR og typespecifik revers hybridisering |
| DE19903056B4 (de) * | 1999-01-26 | 2007-07-19 | Medeea Forschungs-Gmbh | HPV-Assay |
| GB0500996D0 (en) * | 2005-01-18 | 2005-02-23 | Delfts Diagnostic Labaratory B | Detection method and materials therefor |
| US7553955B2 (en) * | 2005-09-01 | 2009-06-30 | The Trustees Of The University Of Pennsylvania | Molecular beacons, methods and kits for detecting DNA damage response |
| US8518639B2 (en) | 2006-04-11 | 2013-08-27 | Bio-Rad Innovations | HPV detection and quantification by real-time multiplex amplification |
| WO2007130519A2 (en) * | 2006-05-02 | 2007-11-15 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Viral nucleic acid microarray and method of use |
| GB0702557D0 (en) * | 2007-02-09 | 2007-03-21 | Health Prot Agency | Detection of human papillomavirus |
| WO2009011472A1 (en) | 2007-07-19 | 2009-01-22 | Hyunil Choi | Primers and proves for detection of high risk group geno-type human papillomavirus dna, a qualitative assay method of the same dna using them and a qualitative assay kit of the same dna |
| NO330943B1 (no) | 2009-04-30 | 2011-08-22 | Unilabs Telelabs As | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. |
-
2009
- 2009-04-30 NO NO20091733A patent/NO330943B1/no not_active IP Right Cessation
-
2010
- 2010-04-22 BR BRPI1007637A patent/BRPI1007637A2/pt not_active IP Right Cessation
- 2010-04-22 NZ NZ596252A patent/NZ596252A/xx not_active IP Right Cessation
- 2010-04-22 SI SI201030881T patent/SI2425017T1/sl unknown
- 2010-04-22 CN CN201080024379.XA patent/CN102459631B/zh not_active Expired - Fee Related
- 2010-04-22 CA CA2760274A patent/CA2760274A1/en active Pending
- 2010-04-22 SG SG2011079480A patent/SG175825A1/en unknown
- 2010-04-22 DK DK10769997T patent/DK2425017T3/da active
- 2010-04-22 MY MYPI2011005207A patent/MY160754A/en unknown
- 2010-04-22 HR HRP20150190TT patent/HRP20150190T1/hr unknown
- 2010-04-22 ES ES10769997.7T patent/ES2534644T3/es active Active
- 2010-04-22 AU AU2010242168A patent/AU2010242168B2/en not_active Ceased
- 2010-04-22 PL PL10769997T patent/PL2425017T3/pl unknown
- 2010-04-22 WO PCT/NO2010/000147 patent/WO2010126375A1/en not_active Ceased
- 2010-04-22 EP EP10769997.7A patent/EP2425017B1/en active Active
- 2010-04-22 US US13/266,943 patent/US8895247B2/en not_active Expired - Fee Related
- 2010-04-22 PT PT107699977T patent/PT2425017E/pt unknown
- 2010-04-22 MX MX2011011521A patent/MX2011011521A/es active IP Right Grant
- 2010-04-22 EA EA201171239A patent/EA201171239A1/ru unknown
- 2010-04-28 SA SA110310331A patent/SA110310331B1/ar unknown
-
2011
- 2011-10-30 IL IL216035A patent/IL216035A0/en unknown
- 2011-11-09 ZA ZA2011/08225A patent/ZA201108225B/en unknown
-
2015
- 2015-02-19 CY CY20151100171T patent/CY1116083T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2425017A4 (en) | 2012-12-26 |
| IL216035A0 (en) | 2012-01-31 |
| BRPI1007637A2 (pt) | 2016-02-23 |
| US20120100528A1 (en) | 2012-04-26 |
| EA201171239A1 (ru) | 2012-05-30 |
| CA2760274A1 (en) | 2010-11-04 |
| CN102459631A (zh) | 2012-05-16 |
| WO2010126375A1 (en) | 2010-11-04 |
| PL2425017T3 (pl) | 2015-07-31 |
| CY1116083T1 (el) | 2017-02-08 |
| US8895247B2 (en) | 2014-11-25 |
| NZ596252A (en) | 2013-06-28 |
| SI2425017T1 (sl) | 2015-05-29 |
| ZA201108225B (en) | 2013-01-30 |
| NO20091733L (no) | 2010-11-01 |
| AU2010242168A1 (en) | 2011-12-01 |
| SG175825A1 (en) | 2011-12-29 |
| SA110310331B1 (ar) | 2014-08-18 |
| PT2425017E (pt) | 2015-02-27 |
| CN102459631B (zh) | 2014-07-02 |
| ES2534644T3 (es) | 2015-04-27 |
| MX2011011521A (es) | 2012-04-19 |
| EP2425017A1 (en) | 2012-03-07 |
| MY160754A (en) | 2017-03-15 |
| EP2425017B1 (en) | 2014-11-19 |
| HRP20150190T1 (hr) | 2015-06-05 |
| NO330943B1 (no) | 2011-08-22 |
| AU2010242168B2 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molijn et al. | Molecular diagnosis of human papillomavirus (HPV) infections | |
| DK2425017T3 (da) | Fremgangsmåde til typebestemmelse af humant papillomvirus HPV | |
| Schmitz et al. | Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types | |
| US11913083B2 (en) | Assay for detecting closely-related serotypes of human papillomavirus (HPV) | |
| Doorn et al. | Molecular detection and genotyping of human papillomavirus | |
| KR100914911B1 (ko) | 실시간 중합효소 연쇄반응과 ｈｐｖ ｄｎａ 칩을 이용한정량 및 정성적 인유두종바이러스 검사 방법 및 이를 위한검사키트 | |
| Li et al. | Detection of human papillomavirus genotypes with liquid bead microarray in cervical lesions of northern Chinese patients | |
| JP4851090B2 (ja) | ヒト・パピローマウイルスを定量的且つ定性的に測定するための方法及びキット | |
| US10947603B2 (en) | HPV detection method | |
| Zhang et al. | A novel fluorescence polarization based assay for 14 human papillomavirus genotypes in clinical samples | |
| WO2025245507A1 (en) | High-risk hpv detection and genotyping using lamp | |
| CN116287442A (zh) | 一种用于检测人乳头瘤病毒的引物探针组合及其应用 | |
| Ennaji | Molecular detection and genotyping of human papillomavirus | |
| WO2005100610A2 (en) | Virus detection method, primers therefor and screening kit |